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Abstract
Objectives: Allogeneic hematopoietic stem cell transplant (HCT) continues to evolve with the
treatment in higher risk patient population. This practice mandates stringent update and val-
idation of risk stratification prior to undergoing such a complex and potentially fatal procedure.
We examined the adoption of the new comorbidity index (HCT-CI/Age) proposed by the Seattle
group after the addition of age variable and compared it to the pre-transplant assessment of
mortality (PAM) that already incorporates age as part of its evaluation criteria.
Methods: A retrospective analysis of adult patients who underwent HCT at our institution from
January 2010 through August 2014 was performed. Kaplan-Meier’s curve, log-rank tests, Cox
model and Pearson correlation was used in the analysis.
Results: Of the 114 patients that underwent allogeneic transplant in our institution, 75.4%
were 40 years old. More than 58% had a DLCO 80%. Although scores were positively corre-
lated (correlation coefficient 0.43, p < 0.001), HCT-CI/Age more accurately predicted 2-year
overall survival (OS) and non-relapse mortality (NRM) in patients with lower (0–4) and higher
https://doi.org/10.1016/j.hemonc.2017.12.002
1658-3876/ 2018 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
q This original research was presented at ASCO Annual meeting in May 2015 in Chicago IL, USA, J Clin Oncol 33, 2015 (suppl; abstr e18004).
* Corresponding author at: Markey Cancer Center, Roach Building, 800 Rose St., cc-410, Lexington, KY 40513, United States. Fax: +1 888
954 7470.
E-mail address: hsa222@uky.edu (H. Saeed).
Hematol Oncol Stem Cell Ther (2018) 11, 90–95
Avai lab le at www.sc iencedi rect .com
ScienceDirect
journal homepage: www.elsevier .com/ locate /hemonc
(5–7) scores (52% and 36% versus 24% and 76%, p = 0.004, 0.003 respectively). PAM score did not
reach statistical significance for difference in OS nor NRM between the low (<24) and high-risk
(24) groups (p = 0.19 for both).
Conclusions: Despite our small sample population, HCT-CI/Age was more discriminative to
identify patients with poor outcome that might benefit from intensified management strategies
or other therapeutic approaches rather than allogeneic HCT.
 2018 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Introduction
Allogeneic hematopoietic cell transplantation often pre-
sents the only curable therapeutic option for patients suf-
fering from hematologic malignancies. While originally
available to the young and fit, it is being increasingly uti-
lized for patients of older age and with more comorbidities
[1]. An inverse correlation of conditioning related toxicity
and a better understanding of the graft versus leukemia
effect, have led to allogeneic HCT being available for those
patients in their 6th and 7th decade of life [2–4].
However, it is crucial to understand treatment related
mortality from HCT in order to better identify those
patients who would benefit from an alternative treatment
approach or intensified supportive measures to optimize
their outcome.
The first attempts to predict outcome were made using
the Charlson comorbidity index (CCI) [5] in 2004 when its
application in 134 allogeneic HCT recipients allowed to pre-
dict non-relapse mortality in myeloablative and non-
myeloablative regimens [6]. The same group used a larger
cohort to create the Hematopoietic stem cell transplant
comorbidity index (HCT-CI), which added variables such as
obesity, psychiatric disturbances and infection to the pre-
transplant evaluation [7]. Since then, this scoring system
has been accepted in multiple institutions as a commonly
used tool for evaluating patients undergoing allogeneic
HCT including our transplant center.
In an attempt to include more variables such as age, dis-
ease status and source of graft as potential factors on trans-
plant outcome, Pariman et al formed a 50 points scoring
system, the pre-transplant assessment of mortality (PAM)
score. Both scoring systems have been validated in different
patient populations [8–11]. Age has been a controversial
predictor in transplant outcome; a study from the US
showed poor prediction of allogeneic HCT mortality when
elderly patients were stratified by age [12]. The European
experience reported similar outcome of patients with age
above 50 [13]. Sorror et al studied the effect of addition
of age to HCT-CI and was able to show that age 40 years
carried worse prognosis and deserved to be amended to
HCT-CI scoring system to facilitate patients’ stratification
prior to transplant [14].
Since this introduction of age variable to HCT-CI score, to
our knowledge, there have been no studies to verify the util-
ity of this new scoring system and how it compares to the
PAM score in an independent patient cohort. We aimed to
compare the two scores and to verify their applicability in
our population.
Methods
This is a retrospective analysis of 114 consecutive patients
who underwent allogeneic HCT at the University of Ken-
tucky between January 2010 and August 2014. The study
was approved by the institutional review board.
Patients and transplant procedure
All adults, 18 years or older, carrying a diagnosis of malig-
nant or benign conditions warranting an allogeneic HCT
were included. Data including pre-transplant organ func-
tion, underlying disease, and donor type (matched sibling
donor (MR), matched unrelated donor (MUD), and mismatch
donor (MMR)) [15]. A match was defined as 10 out of 10 HLA
match. Conditioning regimens were categorized according
to previously defined criteria [16]: Disease was categorized
based on the revised disease risk index [17]. Myeloablative
regimen (MA) included total body irradiation (TBI) of
5 Gy single dose or 8 Gy fractionation, Busulfan (Bu)
>8 mg/kg orally or >4000 AUC intravenously. Non myeloabla-
tive (NMA) regimens included TBI 2 Gy ± a purine analog.
All other regimens were considered reduced intensity regi-
mens (RIC) including regimens containing Bu that do not
meet MA definition, and Fludarabine (Flu)+Melphalan
(Mel). Graft versus host disease (GVHD) prophylaxis was
done with tacrolimus ± methotrexate. In vivo T cell deple-
tion was done with alemtuzumab or ATG as part of condi-
tioning regimen based on treating physician discretion.
Patients were kept in the hospital until neutrophil
engraftment, defined as an absolute neutrophil count >50
0  103/lL for three consecutive days. Acute GvHD was
evaluated based on predefined criteria [18]. PAM score
and HCT-CI/Age were calculated for all patients as
described [14,15].
Statistical analysis and end points
Using the Contal and O’Quigley method [19], the ideal cut-
off points were determined for both PAM (24) and HCT-CI/
Age (5) that would be able to separate the population into
two groups depending on outcome. The cohort was then
divided into two groups (low and high risk) using the prede-
fined cutoff points for both comorbidity scores. Overall sur-
vival (OS) and non-relapse mortality (NRM) rates at two
years were calculated and compared for both groups using
Kaplan-Meier curves and log rank tests and competing risk
methods respectively. Cox models were utilized to calculate
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hazard ratios for OS and NRM for both risk groups using PAM
and HCT-CI/Age using univariate and multivariate analysis.
Pearson correlation was used to study association between
PAM and HCT-CI/Age score. Multivariate analysis was
explored to study whether the comorbidity score has inde-
pendent effect on overall survival at 2 years. Analyses were
run using SAS 9.4 (SAS Institute, Cary NC) and statistical sig-
nificance was defined as p value of <0.05 for all tests.
Results
Baseline characteristics
Medianageof the114patients includedwas53 (range20–69).
Most transplanted patients were 40 year-old (75%, n = 86).
Therewas similar gender distribution. Grafts fromMUD repre-
sented 65% (n = 74), while only 2.6% (n = 3) were MMR. 2.6%
(n = 3) had low-risk disease prior to transplant, and 8.7%
(n = 10) had high-risk disease. The specific underlying disease
and baseline characteristics are shown in (Tables 1 and 2).
Pre-transplant diffusion lung capacity (DLCO) of most
patients (58.5%, n = 62) was 80%, with a median of 77%
(range 52–142%). GvHD prophylaxis was done with tacroli-
mus (100%, n = 114), and methotrexate (83%, n = 94), and
in-vivo T cell depletion was incorporated in the GvHD pro-
phylaxis in 80% (n = 91). Similar number of patients received
T cell depletion with alemtuzumab (38%, n = 43) versus ATG
(42%, n = 48). Reduced intensity conditioning was used in
49% (n = 50), while only 1.7% (n = 2) patients received non-
myeloablative conditioning regimen. Details of the condi-
tioning regimens used are shown in Table 3.
Outcome for patients using stratification by HCT-CI/
Age score
Using HCT-CI/Age score, 92 patients (80.7%) were grouped
into a low-risk (0–4), 21 (18.4%) into high-risk (5–7) cate-
gory with 1 (0.9%) not evaluable. OS at 2 years for the
low-risk group was 52.4% (95% Confidence interval (CI):
Table 1 Baseline characteristics of the full cohort.
Variables N %
Age <40 28 24.6
40 86 75.4
Gender Male 60 52.6
Female 54 47.4
CMV patient Positive 70 61.4
Negative 27 23.7
Unknown 17 14.9
CMV donor Positive 50 43.9
Negative 46 40.4
Unknown 18 15.8
Donor MR 37 32.5
MUD 74 64.9
MMR 3 2.6
Pre-transplant creatinine 1.2 (mg/dL) 105 92.1
>1.2 (mg/dL) 9 7.9
Pretranplant alanine transferase 49 (U/L) 88 77.9
>49 (U/L) 25 22.1
Pretransplant FEV1 >80% 82 78.1
80% 23 21.9
Pretransplant DLCO >80% 44 41.5
80% 62 58.5
Underlying disease AML 49 43.0
ALL 19 16.7
MDS 19 16.7
CML 4 3.5
CLL 5 4.4
MF 5 4.4
HL 4 3.5
NHL 3 2.6
AA 2 1.8
Others (T-PLL, MPN, HLH) 4 3.5
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40.5–63%) versus 23.8% (95% CI: 8.7–43%) for the high-risk
group (p = 0.004) (Fig. 1).
NRM mortality at two years was 36.2% (95% CI: 24.6–
47.8%) versus 75.6% (95% CI: 45.4–90.5%) for the low and
high-risk group respectively (P = 0.004) (Fig. 2).
Using univariate analysis, the hazard ratio (HR) for death
in the high-risk group was 2.26 (95% CI: 1.28–4) with a P =
0.005. When adjusting for other variables (gender, CMV sta-
tus, graft source, acute GvHD grade, and chronic GvHD
severity), HCT-CI/Age risk stratification was the only statis-
tically significant variable to affect survival with a HR of
2.16 (95% CI: 1.11–4.18).
Outcome for patients using stratification by PAM
score
The calculated threshold for the PAM score to best separate
patients by outcome was 24, and 47 patients (41.2%) were
Table 2 Comparison of baseline characteristics between the different groups of the pretransplant scores.
Variables HCT-CI/Age PAM
Low (%) High (%) P Low (%) High (%) P
Age <40 96 4 0.01 56 44 0.24
40 77 23 66 34
Gender Male 80 20 0.39 54 46 0.03
Female 83 17 73 27
CMV patients Positive 81 19 0.45 67 33 0.32
Negative 78 22 59 41
CMV donor Positive 80 20 0.60 72 28 0.07
Negative 80 20 56 44
Donor type MR 81 19 0.70 81 19 0.01
MUD 81 19 54 46
MMR 100 0 67 33
Disease risk index Low 82 18 0.99 76 24 0.32
Intermediate 81 19 58 42
High 82 18 64 36
Conditioning regimen NMA 100 0 0.59 100 0 0.36
RIC 78 22 67 33
MA 84 16 58 42
Table 3 Pretransplant conditioning and GvHD prophylaxis.
N %
Conditioning regimen FLU/MEL 41 36.0
BU/FLU 28 24.6
BU/CY 26 22.8
CY/TBI 17 14.9
ET/TBI 2 1.8
GvHD prophylaxis Tacrolimus 114 100
MTX 94 82.5
In-vivo T cell depletion ATG 48 42.1
Alemtuzumab 43 37.7
Fig. 1 OS by HCT-CI/Age.
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accordingly stratified into low-risk (<24) and 67 (58.8%) into
high-risk (24). There was no difference in the low risk
group for OS at 2 years when compared to the high-risk
group (49.4% versus 43% respectively) (p = 0.199) (Fig. 3).
The 2-year NRM difference between the two groups did
not reach statistical significance either (36.1 versus 50.7%
respectively) (p = 0.190) (Fig. 4).
Using Pearson correlations, we showed a slightly positive
correlation between the HCT-CI/Age and PAM score (corre-
lation coefficient 0.427, p < 0.001).
Discussion
Both HCT-CI/Age and PAM have been described to predict
transplant associated morbidity and mortality. Several stud-
ies have demonstrated different cutoff needs to be used for
different patient cohorts in order to validate the usefulness
of pretransplant scores [9,11,20,21]. Our cutoff for the
HCT-CI/Age was consistent with the one reported by the
Seattle group [14]; however, due to smaller patient number
we elected to divide the patients into two groups rather
than 4. While our population overall tended to be older
and patients received mostly reduced intensity conditioning
and T cell depletion when compared to the original Seattle
cohort, we were still able to retrospectively validate the
ability of the HCT-CI/Age to separate patients into high
and low risk groups with respect to transplant outcome,
hereby supporting the usefulness of the HCT-CI/Age. High-
risk patients at our center had comparable survival at 2
years with high-risk groups reported in previous studies
[7,13,21,22].
The fact that PAM score did not correlate with survival
despite selecting an optimum cutoff point, that should have
translated to best separation in risk groups, possibly relates
to the smaller sample size, however, it may also relate to
differences in our cohort from the original PAM score [15].
In comparison to the population used to develop PAM, we
had older patients, with worse pulmonary function and most
of them had received T cell depletion with RIC HCT. More
recent reports support our findings, showing poor pre-
dictability of PAM in T-cell depleted population [23] and less
strong association with mortality when RIC regimens were
used [24].
Limitations to our study include the retrospective nat-
ure, which could have been affected by selection bias with
respect to transplant eligibility of patients and choice of
conditioning regimen. Our small population size and lack
of variable graft sources make it impractical to translate
those findings to haploidentical and cord blood transplants
[21]. A strength of our study possibly relies in the homoge-
nous selection from a consistent geographical area to sup-
port similarities in environmental and genetic factors.
In summary, our study validates and supports the use the
novel HCT-CI/Age score to predict outcome and to allow for
a more informed counselling process for our patients under-
going allogeneic HCT. Our results further confirm the previ-
ous reported decreased usefulness of the PAM score with
the evolution of allogeneic HCT using RIC approaches
offered to a higher risk patient population.
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